encorafenib
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
Jan 31, 2023